BioProgress and FMC restructure NRobe agreement
BioProgress, the speciality pharma and healthcare company, and Magenta Oral Dose Design, a business unit of FMC Corporation have renegotiated agreements regarding the licensing of NRobe technology.
BioProgress, the speciality pharma and healthcare company, and Magenta Oral Dose Design, a business unit of FMC Corporation have renegotiated agreements regarding the licensing of NRobe technology.
Under the restructured arrangements BioProgress, the licensor of NRobe, will receive enhanced royalties based upon total NRobe income generated by FMC. FMC retains the exclusive rights to NRobe and will be responsible for the continuing development, commercialisation and promotion of this novel oral drug delivery system.
Under separate agreements, BioProgress and FMC will collaborate to endorse the technology in certain pharmaceutical products to be licensed for sale through BioProgress' sales and marketing division Dexo.
NRobe is a solid oral dose system capable of enrobing a variety of powders and particulates within dry polymer films to produce an elegant dose form comparable in appearance to film-coated or gel-dipped tablets, or two-piece hard capsules. This system can deliver benefits such as unique appearance, improved drug release, simplified formulation and processing, and the avoidance of problematic excipients.
Development efforts are currently focused on proprietary product applications, commercial scale manufacturing equipment, and novel polymer films.
